The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Serum Bone Markers CTX, PINP Not Linked with Hip Fracture Risk in Osteoporosis

Serum Bone Markers CTX, PINP Not Linked with Hip Fracture Risk in Osteoporosis

July 7, 2018 • By Anne Harding

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Levels of two bone markers currently recommended for evaluating postmenopausal women with osteoporosis have no association with hip fracture risk, according to a new study using Women’s Health Initiative data.

You Might Also Like
  • Changes in Bone Markers Predict Fracture Reduction with Anti-Resorptive Drug
  • Healthy Diet Linked to Lower Hip Fracture Risk in U.S. Women
  • After Hip Fracture, Earlier Osteoporosis Drug Initiation Tied to Lower Subsequent Fracture Risk

“At least in these postmenopausal women, it was not a useful endeavor to check bone turnover markers to predict hip-fracture risk. That doesn’t mean it wouldn’t apply to men or people who were taking therapy for osteoporosis,” Dr. Carolyn J. Crandall, a professor at David Geffen School of Medicine at the University of California, Los Angeles, tells Reuters Health by phone.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The International Osteoporosis Foundation/International Federation of Clinical Chemistry and Laboratory Medicine (IOF/IFCC) Bone Markers Working Group stated in 2011 that C-terminal telopeptide of type I collagen (CTX) and procollagen type 1 aminoterminal propeptide (PINP) were the “most promising markers” of bone turnover, Dr. Crandall and her team note in the Journal of Bone and Mineral Research, online June 19.1 The IOF/IFCC recommends that serum CTX, a bone resorption marker, and serum PINP, a bone formation marker, be measured by standardized assays and used as reference markers in research.

Studies to date looking at bone turnover markers have focused on fragility or osteoporotic fractures in general, and no studies focusing on hip fracture have required that samples be taken in a fasting state, the authors note. “Because hip fractures are a substantial cause of increased morbidity and mortality, it is of clinical importance to elucidate the ability of serum bone turnover markers to predict hip fracture risk,” they add.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Crandall and her team reviewed data from the WHI study, which included measurements of fasting serum PINP and CTX. Women were followed for about seven years, on average, and self-reported hip fractures were confirmed by physician report. They compared 400 women with incident hip fracture who were not taking osteoporosis medication and 400 controls matched by age, race/ethnicity and blood sampling date.

Multivariate analysis showed no significant association between serum CTX or PINP and hip fracture risk.

The authors note that the findings are clinically relevant, given that the American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis recommend, based on Grade B evidence, that clinicians “consider using bone turnover markers in the initial evaluation of osteoporosis patients. Elevated levels can predict higher fracture risk.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Clinicians are using serum CTX and PINP to predict fracture risk in osteoporosis, Dr. Crandall noted, but this practice is not evidence-based. Some also test for additional bone turnover markers, she adds. “Even those have not really been standardized yet across laboratories in the way that they should be.”

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: bone markers, Fractures, hip fracture, hip fracture risk, Osteoporosis

You Might Also Like:
  • Changes in Bone Markers Predict Fracture Reduction with Anti-Resorptive Drug
  • Healthy Diet Linked to Lower Hip Fracture Risk in U.S. Women
  • After Hip Fracture, Earlier Osteoporosis Drug Initiation Tied to Lower Subsequent Fracture Risk
  • Baseline Bone Measures Predict Risk of Fragility Fracture in Postmenopausal

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.